MAPC Transplantation Confers a more Durable Benefit than AC133 Cell Transplantation in Severe Hind Limb Ischemia

• Main Authors: Xabier L. Aranguren, Beatriz Pelacho, Ivan Peñuelas, Gloria Abizanda, Maialen Uriz, Margarita Ecay, María Collantaes, Miriam Araña, Manu Beerens, Giulia Coppiello, Inés Prieto, Maitane Perez-Ilzarbe, Enrique J. Andreu, Aernout Luttun, Felipe Prósper
• Format: Article
• Language: English
• Published: SAGE Publishing 2011-03-01
• Series: Cell Transplantation
• Online Access: https://doi.org/10.3727/096368910X516592

There is a need for comparative studies to determine which cell types are better candidates to remedy ischemia. Here, we compared human AC133 + cells and multipotent adult progenitor cells (hMAPC) in a mouse model reminiscent of critical limb ischemia. hMAPC or hAC133 + cell transplantation induced a significant improvement in tissue perfusion (measured by microPET) 15 days posttransplantation compared to controls. This improvement persisted for 30 days in hMAPC-treated but not in hAC133 + -injected animals. While transplantation of hAC133 + cells promoted capillary growth, hMAPC transplantation also induced collateral expansion, decreased muscle necrosis/fibrosis, and improved muscle regeneration. Incorporation of differentiated hAC133 + or hMAPC progeny into new vessels was limited; however, a paracrine angio/arteriogenic effect was demonstrated in animals treated with hMAPC. Accordingly, hMAPC-conditioned, but not hAC133 + -conditioned, media stimulated vascular cell proliferation and prevented myoblast, endothelial, and smooth muscle cell apoptosis in vitro. Our study suggests that although hAC133 + cell and hMAPC transplantation both contribute to vascular regeneration in ischemic limbs, hMAPC exert a more robust effect through trophic mechanisms, which translated into collateral and muscle fiber regeneration. This, in turn, conferred tissue protection and regeneration with longer term functional improvement.